Tailored protein-conjugated DNA nanoplatform for synergistic cancer therapy

Liu, Dingkang; Chen, Ye; Wang, Qun; Ji, Yue; Bao, Lichen; Yao, Wenbing; Gao, Xiangdong; Yin, Jun

doi:10.1016/j.jconrel.2022.04.022

Cited by 12 publications

(7 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is quite easy to achieve anti-tumor reagents such as inhibitors, however, as to how to improve the properties of these reagents as drugs, their biological availability, half-life, biocompatibility, and so on, are highly concerned as common issues that might make them more efficient and less harmful to the patients during clinical applications. Till now, hundreds of studies surrounding clinical application of the anti-tumor drugs for curation of MDR cancers, or those focusing on the anti-tumor drug systems with high potential for clinical translation have been published 1 , 5 , 11 , 188 , 189 , 190 , 191 , 192 , 193 , 194 , 195 , 196 , 197 .…”

Section: Prospects For Exploration Of Antitumor Drugs That Can Revers...mentioning

confidence: 99%

Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers

Zhang

Ye²,

Chen³

et al. 2023

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Section: Prospects For Exploration Of Antitumor Drugs That Can Revers...mentioning

confidence: 99%

Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers

Zhang

Ye²,

Chen³

et al. 2023

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

“…Moreover, compared with dendrimers, dendrimer-like polymers have larger internal cavity. [47] Cao et al [48] reported the synthesis of dendritic-like star polymers. The polymers have similar structures with the dendritic macromolecules, using star poly(l-lactide) as the hydrophobic cores and PAMAM as the dendritic shells.…”

Section: Other Dendrimer Micellesmentioning

confidence: 99%

“…Moreover, compared with dendrimers, dendrimer‐like polymers have larger internal cavity. [ 47 ] Cao et al. [ 48 ] reported the synthesis of dendritic‐like star polymers.…”

Section: Classificationmentioning

confidence: 99%

Research Status of Dendrimer Micelles in Tumor Therapy for Drug Delivery

Wang,

Zhang,

et al. 2023

Small

View full text Add to dashboard Cite

Dendrimers are a family of polymers with highly branched structure, well‐defined composition, and extensive functional groups, which have attracted great attention in biomedical applications. Micelles formed by dendrimers are ideal nanocarriers for delivering anticancer agents due to the explicit study of their characteristics of particle size, charge, and biological properties such as toxicity, blood circulation time, biodistribution, and cellular internalization. Here, the classification, preparation, and structure of dendrimer micelles are reviewed, and the specific functional groups modified on the surface of dendrimers for tumor active targeting, stimuli‐responsive drug release, reduced toxicity, and prolonged blood circulation time are discussed. In addition, their applications are summarized as various platforms for biomedical applications related to cancer therapy including drug delivery, gene transfection, nano‐contrast for imaging, and combined therapy. Other applications such as tissue engineering and biosensor are also involved. Finally, the possible challenges and perspectives of dendrimer micelles for their further applications are discussed.

show abstract

“…Our group had previously developed a novel therapeutic protein called PAK, which exhibited prolonged, tumor-targeted release and demonstrated effective antitumor effects in both in vitro and in vivo models [ 19 , 20 ]. This study further confirmed the efficacy of PAK in TNBC.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic protein PAK restrains the progression of triple negative breast cancer through degrading SREBP-1 mRNA

Hu,

Zhou,

Sun

et al. 2023

Breast Cancer Res

Self Cite

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) represents the most challenging subtype of breast cancer. Studies have implicated an upregulation of lipid synthesis pathways in the initiation and progression of TNBC. Targeting lipid synthesis pathways may be a promising therapeutic strategy for TNBC. Our previous study developed a therapeutic protein PAK with passive targeting and inhibiting tumor proliferation. In this study, we further substantiate the efficacy of PAK in TNBC. Transcriptome sequencing analysis revealed PAK-mediated downregulation of genes involved in fatty acid synthesis, including key genes like SREBP-1, FASN, and SCD1. RNA immunoprecipitation experiments demonstrated a significant binding affinity of PAK to SREBP-1 mRNA, facilitating its degradation process. Both in vitro and in vivo models, PAK hampered TNBC progression by downregulating lipid synthesis pathways. In conclusion, this study emphasizes that PAK inhibits the progression of TNBC by binding to and degrading SREBP-1 mRNA, revealing a new strategy for regulating lipid synthesis in the intervention of TNBC and its therapeutic significance.

show abstract

Tailored protein-conjugated DNA nanoplatform for synergistic cancer therapy

Cited by 12 publications

References 47 publications

Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers

Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers

Research Status of Dendrimer Micelles in Tumor Therapy for Drug Delivery

Therapeutic protein PAK restrains the progression of triple negative breast cancer through degrading SREBP-1 mRNA

Contact Info

Product

Resources

About